Literature DB >> 32835767

Nuclear protein 1 imparts oncogenic potential and chemotherapeutic resistance in cancer.

Anthony Murphy1, Max Costa2.   

Abstract

Nuclear protein 1 (NUPR1) also known as p8 and candidate of metastasis 1 (COM1) functions as a transcriptional regulator, and plays a role in cell cycle, DNA damage response, apoptosis, autophagy, and chromatin remodeling in response to various cellular stressors. Since it was first suggested to contribute to cancer development and progression in 1999, a number of studies have sought to reveal its function. However, NUPR1 and its biological relevance in cancer have proven difficult to pinpoint. Based on evidence of NUPR1 expression in cancers, its function extends from carcinogenesis and tumorigenesis to metastasis and chemotherapeutic resistance. A tumor suppressive function of NUPR1 has also been documented in multiple cancers. By and large, literature involving NUPR1 and cancer is confined to pancreatic and breast cancers, yet significant progress has been made with respect to NUPR1 expression and its function in lung, colorectal, blood, and prostate cancers, among others. Recent evidence strongly supports the notion that NUPR1 is key in chemotherapeutic resistance by mediating both anti-apoptotic activity and autophagy when challenged with anti-cancer compounds. Therefore, it is of significant importance to understand the broad range of molecular functions directed by NUPR1. In this review, NUPR1 expression and its role in breast, lung, and colorectal cancer development and progression will be addressed.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Chemotherapeutic resistance; Colorectal cancer; Lung cancer; NUPR1

Mesh:

Substances:

Year:  2020        PMID: 32835767      PMCID: PMC7958295          DOI: 10.1016/j.canlet.2020.08.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  70 in total

1.  The cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion.

Authors:  Ellinor Oxelmark; Jennifer M Roth; Peter C Brooks; Steven E Braunstein; Robert J Schneider; Michael J Garabedian
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 2.  Nontransgenic models of breast cancer.

Authors:  G H Heppner; F R Miller; P M Shekhar
Journal:  Breast Cancer Res       Date:  2000-08-04       Impact factor: 6.466

3.  High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance.

Authors:  Natalie E Simpson; W Marcus Lambert; Renecia Watkins; Shah Giashuddin; S Joseph Huang; Ellinor Oxelmark; Rezina Arju; Tsivia Hochman; Judith D Goldberg; Robert J Schneider; Luiz Fernando Lima Reiz; Fernando Augusto Soares; Susan K Logan; Michael J Garabedian
Journal:  Cancer Res       Date:  2010-09-16       Impact factor: 12.701

4.  Expression of a novel factor, com1, in early tumor progression of breast cancer.

Authors:  A H Ree; M M Pacheco; M Tvermyr; O Fodstad; M M Brentani
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

5.  The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines.

Authors:  Kristina Subik; Jin-Feng Lee; Laurie Baxter; Tamera Strzepek; Dawn Costello; Patti Crowley; Lianping Xing; Mien-Chie Hung; Thomas Bonfiglio; David G Hicks; Ping Tang
Journal:  Breast Cancer (Auckl)       Date:  2010-05-20

Review 6.  Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment.

Authors:  X Sui; R Chen; Z Wang; Z Huang; N Kong; M Zhang; W Han; F Lou; J Yang; Q Zhang; X Wang; C He; H Pan
Journal:  Cell Death Dis       Date:  2013-10-10       Impact factor: 8.469

Review 7.  Behaviour of intrinsically disordered proteins in protein-protein complexes with an emphasis on fuzziness.

Authors:  Johan G Olsen; Kaare Teilum; Birthe B Kragelund
Journal:  Cell Mol Life Sci       Date:  2017-06-08       Impact factor: 9.261

8.  Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.

Authors:  H Naundorf; E C Rewasowa; I Fichtner; B Büttner; M Becker; M Görlich
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.624

9.  Evidence supporting the existence of a NUPR1-like family of helix-loop-helix chromatin proteins related to, yet distinct from, AT hook-containing HMG proteins.

Authors:  Raul Urrutia; Gabriel Velez; Marisa Lin; Gwen Lomberk; Jose Luis Neira; Juan Iovanna
Journal:  J Mol Model       Date:  2014-07-24       Impact factor: 1.810

10.  Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation.

Authors:  Daniel Grasso; Jennifer Bintz; Gwen Lomberk; Maria Ines Molejon; Celine Loncle; Maria Noé Garcia; Maria Belen Lopez; Raul Urrutia; Juan L Iovanna
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

View more
  3 in total

1.  Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells.

Authors:  Lingling Wang; Jiashen Sun; Yueyuan Yin; Yanan Sun; Jinyi Ma; Ruimin Zhou; Xinzhong Chang; Ding Li; Zhi Yao; Shanshan Tian; Kai Zhang; Zhe Liu; Zhenyi Ma
Journal:  Cell Death Dis       Date:  2021-02-04       Impact factor: 8.469

2.  NUPR1 protects against hyperPARylation-dependent cell death.

Authors:  Patricia Santofimia-Castaño; Can Huang; Xi Liu; Yi Xia; Stephane Audebert; Luc Camoin; Ling Peng; Gwen Lomberk; Raul Urrutia; Philippe Soubeyran; Jose Luis Neira; Juan Iovanna
Journal:  Commun Biol       Date:  2022-07-22

Review 3.  Autophagy Takes Center Stage as a Possible Cancer Hallmark.

Authors:  Jose G Alvarez-Meythaler; Yoelsis Garcia-Mayea; Cristina Mir; Hiroshi Kondoh; Matilde E LLeonart
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.